DR. DOPING

Instructions

Logo DR. DOPING

Instructions / Instruction for use: Diprosalic

I want this, give me price

Active substance Betamethasone + Salicylic acid

ATX code D07XC01 Betamethasone in combination with other drugs

Pharmacological group

Glucocorticosteroids in combinations

Nosological classification (ICD-10)

L21 Seborrheic dermatitis

Dermatitis seborrheic, Increased sebum separation, Seborrheic Eczema, Seborrheic dermatitis of the scalp, Seborrheic pyodermatitis, Seborrhea, Eczema seborrheic

L21.0 Seborrhea of the head

Itchy scalp, Dandruff, Increased sebum separation, Seborrhea is oily, Seborrhea of the scalp, Seborrhea of the scalp

L30.1 Dyshidrosis [pomfolix]

Skin dyshidrosis, Pomfolix, Eczema dysgidrotic, Dyshidrotic eczema, Infected dyshidrosis, Dyshidrosis, Dyshidrotic dermatitis

L30.9 Dermatitis, unspecified

Allergic dermatoses complicated by a secondary bacterial infection, Anal eczema, Bacterial maturation, Varicose Eczema, Venous dermatitis, Inflammation of the skin, Inflammation of the skin upon contact with plants, Inflammatory Skin Diseases, Inflammatory skin reactions, Inflammatory processes of the skin, Hypostatic dermatitis, Fungal Eczema, Fungal dermatosis, Dermatitis, Dermatitis is stagnant, Dermatitis and eczema in the anal area, Dermatitis acute contact, Perianal dermatitis, Dermatosis, Dermatosis of the scalp, Dermatosis of psoriasis, Dermatosis with persistent itching, Dermatoses, Dermatoses itchy, Other itching dermatoses, Significant eczematous manifestations, Itching with, dermatoses, Itching eczema, True eczema, Skin reaction to insect bites,Skin itching with dermatosis, Constitutional eczema, Weeping eczema, Drowsing inflammatory skin disease, Dying Infectious-Inflammatory Skin Disease, Non-allergic dermatitis, Nummular eczema, Acute contact eczema, Acute inflammatory skin disease, Acute dermatosis, Acute severe dermatosis, Perianal dermatitis, Superficial dermatosis, Subacute Contact Eczema, Simple dermatitis, Occupational dermatitis, Psychogenic dermatosis, Bubble dermatitis of newborns, Pustular eruptions, Irritation and redness of the skin, Low-flammable eczema, Dry atrophic eczema, Dry eczema, Toxic dermatitis, Ear eczema like dermatitis, Chronic eczema, Chronic dermatosis, Chronic common dermatosis, Scaly papular dermatosis, Eczema, Eczema anal region, Eczema of the hands, Eczema Contact, Eczema lichenized, Eczema Nummular, Eczema acute, Eczema acute contact, Eczema subacute, Eczematous dermatitis, Eczema-like rashes, Ecome exogenous, Endogenous eczema, Gluteal dermatitis, Restricted itchy dermatitis

L40 Psoriasis

Chronic psoriasis with diffuse plaques, Generalized psoriasis, Psoriasis of the scalp, Psoriasis of the scalp, Generalized form of psoriasis, Psoriasis dermatitis, Psoriasis complicated by erythroderma, Invalidative psoriasis, Isolated psoriatic plaque, Exfoliative psoriasis, Psoriatic Erythroderma, Psoriasis with eczematosis, Hyperkeratosis in psoriasis,Inverse psoriasis,Psoriasis eczematous, Dermatosis of psoriasis, Psoriasis of the genitals, Psoriasis with lesions of hairy areas of skin, Erythrodermal psoriasis, Chronic psoriasis of the scalp, Chronic psoriasis, Ordinary psoriasis, Refractory psoriasis, Kebner phenomenon, Scaly lichen

L43 Red Leaf Flat

Lishay Wilson, Erosive-ulcerative form of red flat lichen, Warty forms of red lichen, Red lichen, Flat lichen, Kebner phenomenon

L44.9 Papulovosvamous changes, unspecified

Darya's follicular dyskeratosis, Follicular dyskeratosis, Asbestos Liver, Darya's disease, Dyskeratosis, Papula (nodule)

L85.0 Acquired ichthyosis

Ichthyosis, Ichthyosis and ichthyosis lesions, Ichthyosis and ichthyosis of the skin, Ichthyosis and ichthyosoform changes, Ichthyosiform erythroderma, Ichthyosiform dermatosis

L85.2 Point-to-point keratosis (palmar-plantar)

Hyperkeratosis of the skin, Hyperkeratoses, Hyperkeratosis, Tylotic Eczema, Hyperkeratosis in psoriasis

R23.8.0 * Dryness of the skin

Dry skin on large areas of the skin, Dryness of the skin in violation of the integrity of its covers, Dryness of the skin,Skin peeling

Composition

Solution for external use 1 g

Active substances:

Betamethasone dipropionate 0.64 mg (0.064%)

(Corresponding to 0.5 mg betamethasone)

Salicylic acid 20 mg (2%)

Auxiliary substances: disodium edetate 0.3 mg; Hypromellose 4000 cps - 5 mg; Sodium hydroxide - 5 mg; Isopropanol 392 mg; Water 577.06 mg

Solution for external use in a vial with a nozzle-spray (spray) 1 g

Active substances:

Betamethasone dipropionate 0.64 mg

(Corresponding to 0.5 mg betamethasone)

Salicylic acid 20 mg

Auxiliary substances: disodium edetate 0.3 mg; Hypromellose 4000 cps - 5 mg; Sodium hydroxide - 5 mg; Isopropanol 392 mg; Water 577.06 mg

Description of dosage form

Transparent colorless viscous solution with the smell of isopropanol.

pharmachologic effect

Pharmacological action - anti-inflammatory, anti-edematous, antiallergic, antifungal, immunosuppressive, antipruritic, keratolytic, antiproliferative, antimicrobial.

Pharmacodynamics

Belosalic has a lot of anti-inflammatory, antipruritic, anti-edematous, antiallergic, antiproliferative, immunosuppressive, keratolytic, antimicrobial and antifungal actions.

Betamethasone dipropionate is a synthetic SCS, which has anti-inflammatory, anti-allergic, antipruritic and vasoconstrictive effects. When applied to the surface of the skin, it narrows the vessels, relieves itching, reduces the release of inflammatory mediators (from eosinophils and mast cells), IL-1 and -2, interferon gamma (from lymphocytes and macrophages), inhibits the activity of hyaluronidase and reduces the permeability of the vascular wall. Interacts with specific receptors in the cytoplasm of the cell, stimulates the synthesis of mRNA, inducing the formation of proteins, incl. Lipocortin, mediating cellular effects. Lipocortin depresses phospholipase A2, blocks the release of arachidonic acid and the biosynthesis of endoperoxides, PG, leukotrienes (contributing to the development of inflammation, allergy and other pathological processes).

Salicylic acid due to keratolytic action clears lesions from scales, promotes the penetration of betamethasone into the skin, supports the acidic environment of the skin, preventing the development of bacterial and fungal infection.

Indications

Subacute and chronic dermatoses sensitive to corticosteroid therapy, accompanied by hyperkeratosis and desquamation:

psoriasis;

Seborrheic dermatitis of the scalp;

Asbestos-shaped lichen;

Seborrhea;

Neurodermatitis;

Red flat lichen with localization on the scalp;

eczema;

Ichthyosis;

Skin dyshidrosis.

Contraindications

Hypersensitivity to betamethasone, salicylic acid or any auxiliary component of the drug;

Viral skin infections;

Cutaneous post-vaccination reactions;

Open wounds;

Trophic ulcers;

Acne vulgaris;

Rosacea;

chickenpox;

Cutaneous manifestations of syphilis;

lupus;

Children age up to 6 months.

pregnancy and lactation

Local use of the drug Belosalic® lotion in pregnant women is allowed in cases where the intended benefit to the mother exceeds the risk to the fetus. In such cases, the use of the drug should be short and limited to small areas of skin.

In the period of breastfeeding, use of the drug Belosalic® lotion is possible on strict indications, but the drug should not be applied to the skin of the breast before feeding.

Side effects

Adverse events, as a rule, are reversible and bear a weak character.

On the part of the skin: a hypersensitivity reaction (itching, burning or redness), acne-like changes, hypopigmentation, striae, skin atrophy, hypertrichosis, secondary skin infections.

With continuous continuous uncontrolled application and application to large areas of the skin: telangiectasia, systemic manifestations of side effects of GCS or salicylates.

In case of a hypersensitivity reaction or side effects, therapy should be discontinued and consult a doctor.

Interaction

There were no clinically significant interactions with other drugs (drug). Simultaneous use of cosmetic and dermatological products for external use containing ethanol, or medical soap with a pronounced drying effect can cause skin irritation.

Dosing and Administration

Outwardly.

Vial with spray nozzle

Belosalic® Lotion is sprayed 2 times a day on the affected areas of scalp with hair, using a convenient extended nozzle-sprayer. In some cases, a single application per day is sufficient.

Before spraying, the vial should be shaken, placed in a vertical position, then bring the tip of the nozzle to the affected area of the skin with the scalp and press the index finger until it stops on the sprayer. Make the necessary amount of spray on the affected areas of the scalp.

The duration of treatment is individual, usually before the disappearance of the main symptoms of the disease, but is usually limited to 3-4 weeks. If you need a longer course of therapy, it is recommended to use the drug less often, for example every other day, and consult with a specialist.

Bottle of a dropper

Belosalic® Lotion is used 2 times a day. A few drops of lotion evenly distributed with a cotton swab or fingers on the surface of the skin, lightly rubbing. In some cases, a single use per day is sufficient. Duration of treatment is usually limited to 3-4 weeks. If you need a longer course of therapy, it is recommended to use the drug less often, for example every other day, or consult a specialist. Belosalic® lotion can be given to children from 6 months with caution and for as short a time as possible.

Overdose

Symptoms: manifestation of systemic side effects.

Treatment: withdrawal of the drug and symptomatic therapy.

special instructions

Belosalic® Lotion is for external use only.

Avoid contact with eyes and mucous membranes, as well as the use of the drug in the anogenital area.

It is not recommended to use the drug for occlusive dressings, except when it is necessary. When developing fungal or bacterial microflora on the skin, an additional use of an antibacterial or antifungal agent is necessary.

The preparation Belosalic® lotion in the form of a solution for external use is especially suitable for use on the scalp. The solution is easily distributed over the surface of the skin, does not adhere or dry the hair, leaves no visible traces, has a cooling effect on the skin.

Impact on the ability to manage vehicles and mechanisms. Data on the adverse effects of the drug Belosalic® lotion on the ability to drive vehicles and mechanisms are absent.

Form of issue

Solution for external use. For 50 or 100 ml of the drug in a vial of HDPE with a dropper, sealed with a screw-in stopper made of LDPE. The plug has a ring to control the first opening. On 1 ôë. In a cardboard box.

For 20, 50 or 100 ml of the preparation in a vial of HDPE with a spray pump mechanism and a protective plastic cap. On 1 ôë. In a set with a plastic nozzle-sprayer in a cardboard bundle.

Conditions of leave from pharmacies

Without recipe.

Storage conditions

At a temperature not higher than 25 ° C.

Keep out of the reach of children.

Shelf life

2 years.

Do not use after the expiry date printed on the package.

Someone from the Singapore - just purchased the goods:
Ceraxon injection 500mg/4ml 5 vials